Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Adverse Effects of Low-Dose Methotrexate: A Randomized Trial

Open access
Solomon, Daniel H., Glynn, Robert J., Karlson, Elizabeth W., Lu, Fengxin, Corrigan, Cassandra, Colls, Josh, Xu, Chang, MacFadyen, Jean, Barbhaiya, Medha, Berliner, Nancy, Dellaripa, Paul F., Everett, Brendan M., Pradhan, Aruna D., Hammond, Sarah P., Murray, Meredith, Rao, Deepak A., Ritter, Susan Y., Rutherford, Anna, Sparks, Jeffrey A., Stratton, Jackie, Suh, Dong H., Tedeschi, Sara K., Vanni, Kathleen M.M., Paynter, Nina P., Ridker, Paul M · 2020 · Annals of Internal Medicine

Abstract

Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred. Objective: To investigate AE rates, risk, and risk differences comparing LD-MTX versus placebo. Design: Prespecified secondary analyses of a double-blind, placebo-controlled, randomized trial. (ClinicalTrials.gov: NCT01594333). Setting: North America. Participants: Adults with known cardiovascular disease and diabetes or metabolic syndrome. Intervention: Random allocation to LD-MTX (≤20 mg/wk) or placebo. All participants received folic acid, 1 mg/d, 6 days per week. Measurements: Risks for specific AEs of interest, as well as for all AEs, were compared across treatment groups after blinded adjudication. Results: After an active run-in period, 6158 patients were enrolled and 4786 randomly assigned to a group; median follow-up was 23 months and median dosage 15 mg/wk. Among the randomly assigned participants, 81.2% were male, median age was 65.7 years, and median body mass index was 31.5 kg/m2. Of 2391 participants assigned to LD-MTX, 2080 (87.0%) had an AE of interest, compared with 1951 of 2395 (81.5%) assigned to placebo (hazard ratio [HR], 1.17 [95% CI, 1.10 to 1.25]). The relative hazards of gastrointestinal (HR, 1.91 [CI, 1.75 to 2.10]), pulmonary (HR, 1.52 [CI, 1.16 to 1.98]), infectious (HR, 1.15 [CI, 1.01 to 1.30]), and hematologic (HR, 1.15 [CI, 1.07 to 1.23]) AEs were elevated for LD-MTX versus placebo. With the exception of increased risk for skin cancer (HR, 2.05 [CI, 1.28 to 3.28]), the treatment groups did not differ in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs. Renal AEs were reduced in the LD-MTX group (HR, 0.85 [CI, 0.78 to 0.93]). Limitation: The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active run-in period. Conclusion: Use of LD-MTX was associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased. Primary Funding Source: National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m19-3369

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 227

Metadata

Authors
Solomon, D. H., Glynn, R. J., Karlson, E. W., Lu, F., Corrigan, C., Colls, J., Xu, C., MacFadyen, J., Barbhaiya, M., Berliner, N., Dellaripa, P. F., Everett, B. M., Pradhan, A. D., Hammond, S. P., Murray, M., Rao, D. A., Ritter, S. Y., Rutherford, A., Sparks, J. A., Stratton, J., Suh, D. H., Tedeschi, S. K., Vanni, K. M. M., Paynter, N. P., & Ridker, P. M.
Venue
Annals of Internal Medicine
Published
2020-03-17
Volume
172
Issue
6
Pages
369-380
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W3007527874
Cited by
227
References
5
FWCI
19.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. https://app.cochat.ai/papers/10.7326/m19-3369
The paper
Solomon, D. H., Glynn, R. J., Karlson, E. W., Lu, F., Corrigan, C., Colls, J., Xu, C., MacFadyen, J., Barbhaiya, M., Berliner, N., Dellaripa, P. F., Everett, B. M., Pradhan, A. D., Hammond, S. P., Murray, M., Rao, D. A., Ritter, S. Y., Rutherford, A., Sparks, J. A., . . . Ridker, P. M. (2020). Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/m19-3369

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.